(Source: Enanta Pharmaceuticals Inc) Decision from FDA on New Drug Application anticipated in second half of 2016 Regimen contains Enanta’s lead protease inhibitor, paritaprevir WATERTOWN, Mass.--(BUSINESS WIRE)--Dec. 2, 2015-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced AbbVie’s New Drug Application (NDA) has been accepted by the U.S. Food and Drug Administration (FDA) for a once-daily, fixed-dose formulation of the components of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets). VIEKIRA PAK is an...
↧
